NCT07320963 2026-03-20
Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 1/2 Not yet recruiting
Clinical Trials
14 trialsNCT07193186 2026-02-27
Anlotinib and Benmelstobart in DTC
Fudan University
Phase 2 Not yet recruiting
NCT06195228 2025-08-14
A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
Fudan University
Phase 4 Recruiting
NCT07010393 2025-06-08
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study
Fujian Medical University
Phase 4 Not yet recruiting
NCT06851247 2025-02-28
GAPP Induction and Concurrent Chemoradiotherapy Followed by Toripalimab Maintenance for Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 2 Recruiting
NCT04996758 2024-12-12
Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)
Sun Yat-sen University
Phase 2 Completed
NCT06482086 2024-12-05
Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer
West China Hospital
Phase 2 Recruiting
NCT06699498 2024-11-21
Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT03906058 2023-10-25
Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy
Sun Yat-sen University
Phase 2 Completed
NCT05659186 2022-12-21
PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
West China Hospital
Phase 2 Unknown
NCT04999800 2021-08-11
Study of Pembrolizumab Combined With Anlotinib in the First Line Therapy for R/M HNSCC With CPS≥1
ChineseAMS
Phase 2 Unknown
NCT04309136 2021-04-01
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
Fudan University
Phase 2 Unknown
NCT02586337 2019-05-21
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2/3 Unknown
NCT03639467 2018-09-18
Study of Anlotinib Combined With Gemcitabine/Cisplatin in Advanced Nasopharyngeal Carcinoma
ChineseAMS
Phase 1/2 Unknown